Atara Biotherapeutics Inc (ATRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has a cash flow conversion efficiency ratio of 0.267x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.79 Million) by net assets ($-36.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATRA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Atara Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Atara Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atara Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gadang Holdings Bhd
KLSE:9261
|
0.000x |
|
Adcorp
JSE:ADR
|
-0.111x |
|
Avecho Biotechnology Ltd
AU:AVE
|
-2.199x |
|
Inter Industries
TA:ININ
|
0.229x |
|
Cyviz AS
OL:CYVIZ
|
0.488x |
|
City Of London Investment Trust
LSE:CTY
|
0.005x |
|
WINSON Machinery Co Ltd
TWO:4538
|
0.020x |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
0.063x |
Annual Cash Flow Conversion Efficiency for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Atara Biotherapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Atara Biotherapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-97.28 Million | $-68.72 Million | 0.706x | -63.68% |
| 2023-12-31 | $-99.23 Million | $-192.98 Million | 1.945x | +191.07% |
| 2022-12-31 | $126.64 Million | $-270.43 Million | -2.135x | -170.76% |
| 2021-12-31 | $279.61 Million | $-220.52 Million | -0.789x | -101.72% |
| 2020-12-31 | $462.34 Million | $-180.76 Million | -0.391x | +51.75% |
| 2019-12-31 | $290.78 Million | $-235.63 Million | -0.810x | -52.74% |
| 2018-12-31 | $338.86 Million | $-179.77 Million | -0.531x | -7.84% |
| 2017-12-31 | $177.86 Million | $-87.50 Million | -0.492x | -107.96% |
| 2016-12-31 | $253.74 Million | $-60.02 Million | -0.237x | -100.62% |
| 2015-12-31 | $315.10 Million | $-37.16 Million | -0.118x | +26.83% |
| 2014-12-31 | $103.18 Million | $-16.63 Million | -0.161x | -129.76% |
| 2013-12-31 | $-11.02 Million | $-5.97 Million | 0.542x | -18.45% |
| 2012-12-31 | $-3.73 Million | $-2.48 Million | 0.664x | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more